Dr. Yardley on Current Recommendations for ER+ Breast Cancer Treatment

Denise A. Yardley, MD
Published: Wednesday, Oct 25, 2017



Denise A. Yardley, MD, senior investigator of breast cancer research, Sarah Cannon Research Institute, discusses current recommendations for estrogen receptor (ER)-positive breast cancer treatment.

The recommendations for adjuvant endocrine therapy are still evolving and utilizes tamoxifen with premenopausal patients. The recent data with axillary dissection with access minimized (ADAM), adjuvant tamoxifen longer against shorter (ATLAS), and extending the therapy from tamoxifen from 5 to 10 years are consistent.

Oncologists are currently tailoring adjuvant endocrine therapy to each patient. Additionally, there have been mixed results from clinical trials, such as the MA17R and the NSABP-42 studies.
SELECTED
LANGUAGE


Denise A. Yardley, MD, senior investigator of breast cancer research, Sarah Cannon Research Institute, discusses current recommendations for estrogen receptor (ER)-positive breast cancer treatment.

The recommendations for adjuvant endocrine therapy are still evolving and utilizes tamoxifen with premenopausal patients. The recent data with axillary dissection with access minimized (ADAM), adjuvant tamoxifen longer against shorter (ATLAS), and extending the therapy from tamoxifen from 5 to 10 years are consistent.

Oncologists are currently tailoring adjuvant endocrine therapy to each patient. Additionally, there have been mixed results from clinical trials, such as the MA17R and the NSABP-42 studies.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication
x